ABSORPTION AND DISPOSITION OF MULTIPLE DOSE FTY720 IN HUMANS.
Somesh Choudhury(Octane Wireless (United States)), Tomasz Sablinski(Icahn School of Medicine at Mount Sinai), Allen B. Leichtman(University of Michigan), Robert Schmouder(Novartis (United States)), Barry D. Kahan(University of Houston), Janet L. Karlix(UF Health Shands Hospital), Ronald M. Ferguson(Instituto do Sono), Lawrence Chodoff(Octane Wireless (United States))
Cited by 6
Related Papers
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
|Journal of the American Society of Nephrology|2002|274
A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
|Arthritis & Rheumatism|2006|255
REMOVAL OF ANTI-PORCINE NATURAL ANTIBODIES FROM HUMAN AND NONHUMAN PRIMATE PLASMA IN VITRO AND IN VIVO BY A Gal??1-3Gal??1-4??Glc-X IMMUNOAFFINITY COLUMN
|Transplantation|1998|196
Specific tolerance across a discordant xenogeneic transplantation barrier.
|Proceedings of the National Academy of Sciences|1994|116
Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients
|American Journal of Transplantation|2003|103